Research Development(RD)13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7(CD7)+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
NeoplasmsHematologic NeoplasmsHematologic Diseases
Interventions
DRUG

RD13-02 cell infusion

CAR-T cells

Trial Locations (1)

221000

Affiliated hospital of Xuzhou medical college, Xuzhou

All Listed Sponsors
collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

Kai Lin Xu,MD

OTHER